People · Operator

David J. Kipnis

Named in public records as an officer, director or promoter · active 2010–2010 · Pharmaceuticals

1
Companies
1
Filings
$80.9M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Intra Cellular Therapies IncPharmaceuticalsSeries C$80.9M$2.1B2010
Operator network

David J. Kipnis at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Joel Marcus · 9 companies · 1 sharedJoel MarcusRichard Lerner · 5 companies · 1 sharedRichard LernerAllen Fienberg · 2 companies · 1 sharedAllen FienbergKimberly Vanover · 2 companies · 1 sharedKimberly VanoverLawrence Hineline · 2 companies · 1 sharedLawrence HinelineLawrence Wennogle · 2 companies · 1 sharedLawrence WennogleSharon Mates · 2 companies · 1 sharedSharon MatesChristopher Alafi · 1 companies · 1 sharedChristopher AlafiChristopher J. Alafi · 1 companies · 1 sharedChristopher J. Al…Joel J. Marcus · 1 companies · 1 sharedJoel J. MarcusLawrence J. Hineline · 1 companies · 1 sharedLawrence J. Hinel…Michael Rawlins · 1 companies · 1 sharedMichael RawlinsRichard J. Lerner · 1 companies · 1 sharedRichard J. LernerSir Michael J. Rawlins · 1 companies · 1 sharedSir Michael J. Ra…Intra Cellular Therapies Inc · $80.9M raisedIntra Cellular Therap…David J. KipnisDK
David J. Kipnis Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside David J. Kipnis on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Joel Marcus19
Richard Lerner15
Lawrence Wennogle12
Kimberly Vanover12
Sharon Mates12
Allen Fienberg12
Lawrence Hineline12
Christopher Alafi11
Joel J. Marcus11
Richard J. Lerner11
Christopher J. Alafi11
Lawrence J. Hineline11
Michael Rawlins11
Sir Michael J. Rawlins11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.